Insys Therapeutics’ (NASDAQ:INSY) investors have suffered a seemingly endless barrage of bad news since 2015. The company’s one and only commercial drug -- Subsys -- has been marred by allegations of improper marketing, and delays in launching a new liquid formulation of the long-standing marijuana drug Marinol haven’t helped boost investor morale, either.
